Investor Novartis Institutes for BioMedical Research, Inc.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Novartis Institutes for BioMedical Research, Inc. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2023-02-08 13G THRD / Third Harmonic Bio, Inc. 2,642,762
2022-10-31 13G/A AYLA / Ayala Pharmaceuticals Inc 698,777 698,777
2022-08-31 13G/A PLRX / Pliant Therapeutics, Inc. 2,153,526 2,153,526
2021-02-08 13G/A SURF / Surface Oncology Inc 3,948,482 3,948,482
2021-02-05 13G AYLA / Ayala Pharmaceuticals Inc 698,777
2021-01-22 13D/A NTLA / Intellia Therapeutics, Inc. 4,352,295 2,176,148
2020-08-20 13D/A NTLA / Intellia Therapeutics, Inc. 4,352,295 4,352,295
2020-06-15 13G PLRX / Pliant Therapeutics, Inc. 2,153,526
2020-03-30 13D/A NTLA / Intellia Therapeutics, Inc. 4,277,073 4,352,295
2020-03-10 13G/A FIXX / Homology Medicines, Inc. 1,979,226 1,979,226
2019-02-04 13G FIXX / Homology Medicines, Inc. 1,979,226
2018-04-23 13G SURF / Surface Oncology Inc 3,948,482
2018-03-23 13D/A NTLA / Intellia Therapeutics, Inc. 4,129,903 4,277,073
2017-12-14 13D/A NTLA / Intellia Therapeutics, Inc. 5,573,658 4,129,903
2016-05-11 13D NTLA / Intellia Therapeutics, Inc. 5,573,658